Drugs / SRP1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07359066 | Jan 2026 → Feb 2028 expected | cancer | Shanghai SciBrunch Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRP1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07359066 ↗ |
| Action | Inhibit | “highly selective PARP1 inhibitor” NCT07359066 ↗ |
| Target | PARP1 | “highly selective PARP1 inhibitor” NCT07359066 ↗ |